Clinical Trial Update: Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy [Phase 1]

View source ↗

Summary

Phase 1 trial update of Suberoylanilide Hydroxamic Acid (SAHA) in adults with advanced solid tumors that failed prior therapy; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma
• Multiple Myeloma and Plasma Cell Neoplasms
• Prostate Cancer
• Small Intestine Cancer

Drugs mentioned

• Zolinza (vorinostat)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Leukemia, Lymphoma | Phase 1 | Status: COMPLETED